Amit Bar‐Or

48.4k citations

453 papers · 25.9k indexed · 8 hit papers · h-index 83

Impact in

Pathology and Forensic Medicine top 0.01%
- Multiple Sclerosis Research Studies
Neurology top 0.05%
- Peripheral Neuropathies and Disorders
- Neuroinflammation and Neurodegeneration Mechanisms

Papers in

Pathology and Forensic Medicine 275
- Multiple Sclerosis Research Studies 270
Immunology 144
- Immunotherapy and Immune Responses 68
- T-cell and B-cell Immunology 54
- Immune Cell Function and Interaction 26

Co-authors: Jack P. Antel Douglas L. Arnold Ludwig Kappos Rui Li Emmanuelle Waubant Robert J. Fox Brenda Banwell Martin Duddy
Journals: Neurology (115 papers)Multiple Sclerosis Journal (49 papers)The Journal of Immunology (20 papers)Multiple Sclerosis and Related Disorders (18 papers)Annals of Neurology (18 papers)
Partner nations: Canada United States Germany

In The Last Decade

Amit Bar‐Or

436 papers receiving 25.4k citations

Hit Papers

8 papers align trajectories log scale

Bruton tyrosine kinase inhibitors for multiple sclerosis 2023 · 101 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Reviews Neurology
2018 Nature Reviews Disease Primers
2012 The Journal of Experimental Medicine
2012 Neurology
2012 New England Journal of Medicine
2011 The Lancet
2008 New England Journal of Medicine
2007 The Journal of Immunology

Peers

Countries citing papers authored by Amit Bar‐Or

Since Specialization

Citations

This map shows the geographic impact of Amit Bar‐Or's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit Bar‐Or with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit Bar‐Or more than expected).

Fields of papers citing papers by Amit Bar‐Or

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit Bar‐Or. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit Bar‐Or. The network helps show where Amit Bar‐Or may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Amit Bar‐Or, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amit Bar‐Or Line = papers co-authored together Amit Bar‐Or links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents Blood ·Caroline Diorio, Софья Борисовна Владимирова, Diego A. Espinoza, Brenda Banwell, Amit Bar‐Or, Amanda M. DiNofia, Allison Barz Leahy, Zachary Martinez, Regina M. Myers, Sarah Hopkins, Susan R. Rheingold, David T. Teachey, Angela N. Viaene, Lisa Wray, Shannon L. Maude, Stephan A. Grupp, Jennifer L. McGuire	2024	10
2	Diffuse nuclear Overhauser effect MRI contrast changes detected in multiple sclerosis subjects at 7T Brain Communications ·Bruno Araujo Borges, 範之川浦, Nestor Adam Gregg, Fang Liu, Tara C. Abraham, Rashid Osman, Shuhong Wu, Oliveira Duarte João Guilherme de, Ravi Prakash Reddy Nanga, Mark A. Elliott, Amit Bar‐Or, John A. Detre, Alexandra Taylor WIles, Matthew K. Schindler, Ravinder Reddy	2024	1
3	Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients Advances in Therapy ·Yang Mao‐Draayer, Amit Bar‐Or, Т. П. Юшкевич, John Foley, Kyle Smoot, Erin E. Longbrake, Derrick Robertson, Jason P. Mendoza, Umair Shah, 何曼莎, Takahiro Yamanishi, Jennifer Lyons, C A Langton, M. Megala, Fabrizio Giuliani	2024	2
4	Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials The Lancet Neurology ·Xavier Montalbán, Patrick Vermersch, Douglas L. Arnold, Amit Bar‐Or, Bruce Cree, Anne H. Cross, Eva Havrdová, Ludwig Kappos, Olaf Stüve, Heinz Wiendl, Jerry S. Wolinsky, Frank Dahlke, N I Belukhov, Li Shen Loo, Sathej Gopalakrishnan, Yann Hyvert, Andrija Javor, Hans Guehring, Nadia Tenenbaum, Davorka Tomic, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2024	32
5	Intersite brain MRI volumetric biases persist even in a harmonized multisubject study of multiple sclerosis Journal of Neuroimaging ·Shuaishuai Tang, Carly M. O’Donnell, Mark A. Elliott, Shahamat Tauhid, Blake E. Dewey, Renxin Chu, С. С. Давыденко, Govind Nair, Pascal Sati, Anna DuVal, Hrvoje Kap, Amit Bar‐Or, Clyde Markowitz, Matthew K. Schindler, Jonathan Zurawski, Peter A. Calabresi, Daniel S. Reich, Rohit Bakshi, Russell T. Shinohara, (unknown)	2023	6
6	Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis Neurology Neuroimmunology & Neuroinflammation ·Stephen L. Hauser, Amit Bar‐Or, Martin S. Weber, Heidemarie Kletzl, Andreas Guenther, Marianna Manfrini, Fabian Model, François Mercier, Claire Petry, 手崎碧, Harold Koendgen, Terry J. Smith, Ludwig Kappos	2023	28
7	Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis Neurology Neuroimmunology & Neuroinflammation ·Simon Thebault, Sheng Bin Weng, Yan Bao-zhen, A.Yu. Usenko, 김정옥, Leah Zuroff, 徐文伟, Matthew K. Schindler, Charles Y. Chiu, Michael R. Wilson, Joseph R. Berger, Clyde Markowitz, Amit Bar‐Or, R. A. Fuller, Rachel Brandstadter, Amy A. Pruitt, Dina Jacobs	2023	8
8	Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab Multiple Sclerosis and Related Disorders ·Amit Bar‐Or, Kiyong Suk, Ángel Chinea, Barry Hendin, Elisabeth B. Lucassen, Xiangyi Meng, James Stankiewicz, Mark Tullman, Anne H. Cross	2023	3
9	Pathways to cures for multiple sclerosis: A research roadmap Multiple Sclerosis Journal ·Bruce F. Bebo, Mark Allegretta, Douglas Landsman, Kathleen M. Zackowski, Fiona Brabazon, Walter A. Kostich, Timothy Coetzee, Alexander V. Ng, Ruth Ann Marrie, Kelly R. Monk, Amit Bar‐Or, Caroline C. Whitacre	2022	16
10	B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies Nature Reviews Neurology ·Maria Teresa Cencioni, Miriam Mattoscio, Roberta Magliozzi, Amit Bar‐Or, Paolo A. Muraro	2021	153
11	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis Multiple Sclerosis Journal ·Moffat Nyirenda, Giulia Fadda, Luke M. Healy, Ina Mexhitaj, M. Hashiue, Heather Hanwell, М.А. КОНАЕВА, Ayal Rozenberg, Rui Li, Craig S. Moore, Hoon Khim, Trina Johnson, Julia O’Mahony, Douglas L. Arnold, E. Ann Yeh, Ruth Ann Marrie, Shannon E. Dunn, Brenda Banwell, Amit Bar‐Or	2021	12
12	Silent New Brain MRI Lesions in Children with MOG‐Antibody Associated Disease Annals of Neurology ·Giulia Fadda, Brenda Banwell, Patrick Waters, Ruth Ann Marrie, E. Ann Yeh, Julia O’Mahony, Douglas L. Arnold, Amit Bar‐Or, (unknown)	2020	34
13	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers Science Translational Medicine ·Laure Michel, Camille Grasmuck, Marc Charabati, Marc‐André Lécuyer, Stéphanie Zandee, Tessa Dhaeze, Jorge I. Alvarez, Rui Li, Sandra Larouche, Lyne Bourbonnière, Robert Moumdjian, Alain Bouthillier, Boaz Lahav, Pierre Duquette, Amit Bar‐Or, Jennifer L. Gommerman, Evelyn Peelen, Alexandre Prat	2019	47
14	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study Multiple Sclerosis Journal ·Jeffrey A. Cohen, Giancarlo Comi, Douglas L. Arnold, Amit Bar‐Or, Krzysztof Selmaj, Lawrence Steinman, Eva Havrdová, Bruce Cree, Xavier Montalbán, Hans‐Peter Hartung, Vivian Huang, Paul Frohna, Brett E. Skolnick, Ludwig Kappos, (unknown)	2018	39
15	Monophasic demyelination reduces brain growth in children Neurology ·Bérengère Aubert-Broche, Katrin Weier, Giulia Longoni, Vladimir Fonov, Amit Bar‐Or, Ruth Ann Marrie, E. Ann Yeh, Sridar Narayanan, Douglas L. Arnold, Leonard H. Verhey, Brenda Banwell, D. Louis Collins	2017	35
16	Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study mediaTUM (Technical University of Munich) ·Xavier Montalbán, Bernhard Hemmer, Kottil Rammohan, Gavin Giovannoni, J. de Sèze, Amit Bar‐Or, Douglas L. Arnold, Annette Sauter, Algirdas Kakarieka, Donna Masterman, P Chin, Hideki Garren, Jerry S. Wolinsky, Ong Y	2015	36
17	Calcium Supplements and Fracture Prevention New England Journal of Medicine ·Paul S. Giacomini, Imke Metz, David Araújo, Nathalie Arbour, Amit Bar‐Or, (unknown)	2014	5
18	ERCP for Gallstone Pancreatitis New England Journal of Medicine ·Paul S. Giacomini, Imke Metz, David Araújo, Nathalie Arbour, Amit Bar‐Or, (unknown)	2014	3
19	Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS Neurology ·Valérie Batteau, Morgan Snell, Michael Hallett, Jack P. Antel, Amit Bar‐Or, Sergio E. Baranzini, Yves Lapierre, David G. Haegert	2014	22
20	Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis Expert Review of Neurotherapeutics ·Peter J. Darlington, Marie‐Noëlle Boivin, Amit Bar‐Or	2011	38

About Amit Bar‐Or

Amit Bar‐Or is a scholar working on Pathology and Forensic Medicine, Immunology, Neurology, Neurology and Developmental Neuroscience, having authored 453 papers that have together received 25.9k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (270 papers), Peripheral Neuropathies and Disorders (69 papers), Immunotherapy and Immune Responses (68 papers), T-cell and B-cell Immunology (54 papers), Neuroinflammation and Neurodegeneration Mechanisms (48 papers), Polyomavirus and related diseases (43 papers), Sphingolipid Metabolism and Signaling (34 papers) and Immune Cell Function and Interaction (26 papers). The work is most often cited by research in Pathology and Forensic Medicine (14.5k citations), Neurology (4.0k citations), Immunology (9.1k citations), Neurology (5.8k citations) and Developmental Neuroscience (1.3k citations). Amit Bar‐Or has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Jack P. Antel, Douglas L. Arnold, Ludwig Kappos, Rui Li, Emmanuelle Waubant, Robert J. Fox, Brenda Banwell, Martin Duddy, Craig S. Moore and Craig H. Smith. Their work appears in journals such as Neurology, Multiple Sclerosis Journal, The Journal of Immunology, Multiple Sclerosis and Related Disorders and Annals of Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact